SK1572004A3 - Bezvodé kryštalické formy gabapentinu - Google Patents
Bezvodé kryštalické formy gabapentinu Download PDFInfo
- Publication number
- SK1572004A3 SK1572004A3 SK157-2004A SK1572004A SK1572004A3 SK 1572004 A3 SK1572004 A3 SK 1572004A3 SK 1572004 A SK1572004 A SK 1572004A SK 1572004 A3 SK1572004 A3 SK 1572004A3
- Authority
- SK
- Slovakia
- Prior art keywords
- gabapentin
- dehydrated
- crystalline
- following
- monohydrate
- Prior art date
Links
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 title claims abstract description 97
- 229960002870 gabapentin Drugs 0.000 title claims abstract description 45
- WRSFRDZQQUAKNA-UHFFFAOYSA-N 2-[1-(aminomethyl)cyclohexyl]acetic acid;hydrate Chemical compound O.OC(=O)CC1(CN)CCCCC1 WRSFRDZQQUAKNA-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 8
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 6
- 239000011877 solvent mixture Substances 0.000 claims description 5
- YUWFEBAXEOLKSG-UHFFFAOYSA-N hexamethylbenzene Chemical compound CC1=C(C)C(C)=C(C)C(C)=C1C YUWFEBAXEOLKSG-UHFFFAOYSA-N 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 238000005481 NMR spectroscopy Methods 0.000 claims description 2
- 239000002274 desiccant Substances 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims 6
- 230000018044 dehydration Effects 0.000 claims 1
- 238000006297 dehydration reaction Methods 0.000 claims 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 150000004682 monohydrates Chemical class 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000001144 powder X-ray diffraction data Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000279 solid-state nuclear magnetic resonance spectrum Methods 0.000 description 2
- XBUDZAQEMFGLEU-UHFFFAOYSA-N 2-[1-(aminomethyl)cyclohexyl]acetic acid;hydron;chloride Chemical compound Cl.OC(=O)CC1(CN)CCCCC1 XBUDZAQEMFGLEU-UHFFFAOYSA-N 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000005388 cross polarization Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
- C07C227/42—Crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32837501P | 2001-10-09 | 2001-10-09 | |
| US10/256,155 US6800782B2 (en) | 2001-10-09 | 2002-09-25 | Anhydrous crystalline forms of gabapentin |
| PCT/US2002/031706 WO2003031391A1 (fr) | 2001-10-09 | 2002-10-03 | Nouvelles formes cristallines anhydres de gabapentine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK1572004A3 true SK1572004A3 (sk) | 2005-03-04 |
Family
ID=26945177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK157-2004A SK1572004A3 (sk) | 2001-10-09 | 2002-10-03 | Bezvodé kryštalické formy gabapentinu |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6800782B2 (fr) |
| EP (1) | EP1463712A1 (fr) |
| JP (1) | JP2005505594A (fr) |
| KR (1) | KR20050033525A (fr) |
| CN (1) | CN1568305A (fr) |
| AP (1) | AP2004003025A0 (fr) |
| BG (1) | BG108702A (fr) |
| BR (1) | BR0213156A (fr) |
| CA (1) | CA2462331A1 (fr) |
| CO (1) | CO5570697A2 (fr) |
| CZ (1) | CZ2004416A3 (fr) |
| EA (1) | EA006557B1 (fr) |
| GE (1) | GEP20063936B (fr) |
| HR (1) | HRP20040408A2 (fr) |
| HU (1) | HUP0401782A3 (fr) |
| IL (1) | IL161099A0 (fr) |
| IS (1) | IS7195A (fr) |
| MA (1) | MA27072A1 (fr) |
| MX (1) | MXPA04003301A (fr) |
| NO (1) | NO20041370L (fr) |
| NZ (1) | NZ531993A (fr) |
| OA (1) | OA12665A (fr) |
| PL (1) | PL368117A1 (fr) |
| RS (1) | RS28204A (fr) |
| SK (1) | SK1572004A3 (fr) |
| TN (1) | TNSN04055A1 (fr) |
| WO (1) | WO2003031391A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070043236A1 (en) * | 2003-05-19 | 2007-02-22 | Chandiran Thakashina M | Process for preparation of gabapentin |
| WO2004106281A1 (fr) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Gabapentine cristallin |
| WO2004110342A2 (fr) * | 2003-06-12 | 2004-12-23 | Matrix Laboratories Ltd | Nouveau polymorphe de gabapentine et sa conversion en gabapentine de forme ii |
| US7169812B2 (en) * | 2003-07-01 | 2007-01-30 | Medtronic, Inc. | Process for producing injectable gabapentin compositions |
| ITMI20040579A1 (it) * | 2004-03-25 | 2004-06-25 | Zambon Spa | Processo di preparazione di gabapentina |
| WO2010023694A2 (fr) * | 2008-09-01 | 2010-03-04 | Hikal Ltd | Formes cristallines de la gabapentine et leur procédé |
| CN104649921B (zh) * | 2015-01-14 | 2016-09-28 | 天津大学 | 一种加巴喷丁与己二酸共晶及其制备方法 |
| CN116693410B (zh) * | 2023-06-08 | 2024-06-07 | 浙江竹子制药有限公司 | 一种粒径可控的加巴喷丁制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4087544A (en) * | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| JPS62247160A (ja) * | 1986-03-31 | 1987-10-28 | Aisin Seiki Co Ltd | スタ−リングエンジンの始動装置 |
| US4894476A (en) * | 1988-05-02 | 1990-01-16 | Warner-Lambert Company | Gabapentin monohydrate and a process for producing the same |
| US4960931A (en) * | 1988-05-02 | 1990-10-02 | Warner-Lambert Company | Gabapentin mohohydrate and a process for producing the same |
| DE3928184A1 (de) * | 1989-08-25 | 1991-02-28 | Goedecke Ag | Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte |
| IL119890A (en) | 1996-12-24 | 2002-03-10 | Teva Pharma | Gabapentin form iii and preparation of gabapentin form ii |
| ES2137137B1 (es) | 1998-05-25 | 2000-08-16 | Medichem Sa | Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica. |
-
2002
- 2002-09-25 US US10/256,155 patent/US6800782B2/en not_active Expired - Fee Related
- 2002-10-03 IL IL16109902A patent/IL161099A0/xx unknown
- 2002-10-03 PL PL02368117A patent/PL368117A1/xx not_active Application Discontinuation
- 2002-10-03 AP APAP/P/2004/003025A patent/AP2004003025A0/en unknown
- 2002-10-03 WO PCT/US2002/031706 patent/WO2003031391A1/fr not_active Ceased
- 2002-10-03 JP JP2003534375A patent/JP2005505594A/ja active Pending
- 2002-10-03 CN CNA02820056XA patent/CN1568305A/zh active Pending
- 2002-10-03 HU HU0401782A patent/HUP0401782A3/hu unknown
- 2002-10-03 GE GE5594A patent/GEP20063936B/en unknown
- 2002-10-03 RS YU28204A patent/RS28204A/sr unknown
- 2002-10-03 KR KR1020047005149A patent/KR20050033525A/ko not_active Ceased
- 2002-10-03 MX MXPA04003301A patent/MXPA04003301A/es active IP Right Grant
- 2002-10-03 NZ NZ531993A patent/NZ531993A/en unknown
- 2002-10-03 CA CA002462331A patent/CA2462331A1/fr not_active Abandoned
- 2002-10-03 OA OA1200400095A patent/OA12665A/en unknown
- 2002-10-03 CZ CZ2004416A patent/CZ2004416A3/cs unknown
- 2002-10-03 HR HR20040408A patent/HRP20040408A2/hr not_active Application Discontinuation
- 2002-10-03 SK SK157-2004A patent/SK1572004A3/sk not_active Application Discontinuation
- 2002-10-03 EP EP02766485A patent/EP1463712A1/fr not_active Withdrawn
- 2002-10-03 BR BR0213156-0A patent/BR0213156A/pt not_active IP Right Cessation
- 2002-10-03 EA EA200400417A patent/EA006557B1/ru not_active IP Right Cessation
-
2004
- 2004-03-23 IS IS7195A patent/IS7195A/is unknown
- 2004-04-01 NO NO20041370A patent/NO20041370L/no not_active Application Discontinuation
- 2004-04-05 MA MA27606A patent/MA27072A1/fr unknown
- 2004-04-06 CO CO04032599A patent/CO5570697A2/es not_active Application Discontinuation
- 2004-04-07 TN TNP2004000055A patent/TNSN04055A1/fr unknown
- 2004-04-28 BG BG108702A patent/BG108702A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20040408A2 (en) | 2004-10-31 |
| WO2003031391A1 (fr) | 2003-04-17 |
| GEP20063936B (en) | 2006-10-10 |
| KR20050033525A (ko) | 2005-04-12 |
| MA27072A1 (fr) | 2004-12-20 |
| NO20041370L (no) | 2004-04-01 |
| EA006557B1 (ru) | 2006-02-24 |
| IL161099A0 (en) | 2004-08-31 |
| EP1463712A1 (fr) | 2004-10-06 |
| CA2462331A1 (fr) | 2003-04-17 |
| BG108702A (en) | 2005-05-31 |
| HUP0401782A3 (en) | 2006-01-30 |
| RS28204A (sr) | 2006-12-15 |
| PL368117A1 (en) | 2005-03-21 |
| US20030092933A1 (en) | 2003-05-15 |
| TNSN04055A1 (fr) | 2006-06-01 |
| US6800782B2 (en) | 2004-10-05 |
| CZ2004416A3 (cs) | 2005-03-16 |
| JP2005505594A (ja) | 2005-02-24 |
| NZ531993A (en) | 2006-09-29 |
| BR0213156A (pt) | 2004-09-14 |
| CO5570697A2 (es) | 2005-10-31 |
| OA12665A (en) | 2006-06-19 |
| EA200400417A1 (ru) | 2004-10-28 |
| IS7195A (is) | 2004-03-23 |
| MXPA04003301A (es) | 2004-07-23 |
| AP2004003025A0 (en) | 2004-06-30 |
| CN1568305A (zh) | 2005-01-19 |
| HUP0401782A2 (hu) | 2005-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200339599A1 (en) | Polymorphic forms alpha, beta and gamma of rifaximin | |
| JP4138886B2 (ja) | ２−アミノ−４−（４−フルオルベンジルアミノ）−１−エトキシカルボニル−アミノベンゼンの新規変態ならびにその製造法 | |
| EP2597090A1 (fr) | Hydrate de dapagliflozine cristalline | |
| JP2005139161A (ja) | リファキシミンの多形体、その製造方法および医薬製剤におけるその使用 | |
| EP0579681B1 (fr) | Monohydrate d'hydrochlorure de tiagabine cristalline, sa preparation et son utilisation | |
| SK1572004A3 (sk) | Bezvodé kryštalické formy gabapentinu | |
| JP2023062038A (ja) | ガドブトロールの製造方法 | |
| US20050272775A1 (en) | Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof | |
| WO2000078729A1 (fr) | Formes cristallines du lansoprazole | |
| FI62311B (fi) | Foerfarande foer framstaellning av kristallint natrium- och kaiumcefalexinmonohydrat | |
| HUP0200006A2 (en) | Crystal modification c of 8-cyano-1-cyclopropyl-7- (1s, 6s-2,8-diazabicyclo - [4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid process for their preparation, pharmaceutical composition comprising thereof and their use | |
| EP2072510A1 (fr) | Forme cristalline d'azélastine | |
| WO2020016827A1 (fr) | Chlorhydrate de détomidine monohydraté sous forme cristalline purifiée, anhydrate de détomidine et base libre de détomidine présentant de faibles quantités d'iso-détomidine et d'autres impuretés, obtenus par recristallisation dans l'eau | |
| AU2002330220A1 (en) | New anhydrous crystalline forms of gabapentin | |
| JP2576598B2 (ja) | 光学活性１−メチル−３−フェニルプロピルアミンの製法 | |
| JPS6072848A (ja) | Ｌまたは（ｓ）−３−（３．４−ジヒドロキシフエニル）−２−メチルアラニンエステルの結晶性塩およびその製法 | |
| KR20190005679A (ko) | 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법 | |
| JPH06102671B2 (ja) | ３―ヒドロキシ―５―（ヒドロキシメチル）―２―メチルイソニコチンアルデヒドホスフェートの薬理活性塩誘導体 | |
| UA77021C2 (en) | A method for the preparation of crystalline dehydrate of gabapentin of form b, crystalline dehydrates of gabapentin of form a and form b | |
| EP1771416A1 (fr) | Nouveau polymorphe de (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochlorure (hydrochlorure de donepezil) et son procede de production | |
| JPWO1992020683A1 (ja) | （−）−（ｓ）−２，８−ジメチル−３−メチレン−１−オキサ−８−アザスピロ［４．５］デカン ｌ−酒石酸塩 | |
| CA2800016A1 (fr) | Formes polymorphes de la warfarine potassique et ses preparations | |
| HU226912B1 (en) | New paroxetin salt and medicament containing it | |
| JPH03153648A (ja) | 光学活性１―メチル―３―フェニルプロピルアミンの製法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |